Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 1, 1997, Pages 84-85

  Lincoln, Sarah ^a,e   Blessing, John A ^b   McGehee, Ramon ^c   Lentz, Samuel S ^d  

^a RUSH MEDICAL COLLEGE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced squamous cell carcinoma of the cervix; Piroxantrone

Indexed keywords

OXANTHRAZOLE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZOLES; UTERINE CERVICAL NEOPLASMS;

EID: 0031023243     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199702000-00019     Document Type: Article

References (16)

1. Schowalter HD, Johnson JL, Hofteizer JM, et al. Anthrapyrazole anticancer agents: Synthesis and structure activity relationships against murine leukemias. J Med Chem 1987;30: 121-31.
2. Leopold WR, Nelson JM, Plowman J, et al. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res 1985;45: 5532-9.
3. Burchenal JH, Pancoast T, Elslager E. Anthrapyrazole and amacrine analogues in mouse and human leukemia in vitro and in vivo. [Abstract] Proc Am Assoc Cancer Res 1985;26:224.
4. NCI Oxantrazole NSC 349174, Division of Cancer Treatment, National Cancer Institute Clinical Brochure, Bethesda, MD. 1987.
5. Leyland-Jones B, Chun HG, Grem JL, et al. Investigational new agents, In: Chabner BA, Collins JM, eds, Cancer chemotherapy: principles and practice. New York: Lippincott, 1990: 491-530.
6. Sebolt JS, Havlick MJ, Hamelehle KL, et al. Establishment of adriamycin-resistant mammary adenocarcinoma 16/C in vitro and its sensitivity to the anthrapyrazoles CI-942 and CI-937. [Abstract] Proc Am Assoc Cancer Res 1985;26:339.
7. Hantel A, Donehower RC, Rowinsky EK, et al. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 1990;50:3284-8.
8. Ames MM, Loprinzi CL, Collins JM, et al. Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride. Cancer Res 1990;50:3905-9.
9. Barlow JJ, Piver MS, Chuang JT, et al. Adriamycin and bleomycin, alone and in combination, in gynecologic cancers. Cancer 1973;32:735-43.
10. Tan C, Etcubanas E, Wollner N, et al. Adnamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973;32:9-17.
11. O'Bryan RM, Luce JK, Talley RW, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
12. Piver MS, Barlow JJ, Xynos Francis P. Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina. Am J Obstet Gynecol 1978;131:311-13.
13. Wallace HJ Jr, Hreshchyshyn MM, Wilbanks GD, et al. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 1978;62:1435-41.
14. Sutton GP, Blessing JA, Barrett RJ, Gallup DG. Phase II trial of menogaril in patients with squamous carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 1994;52:229-31.
15. McGuire WP, Blessing JA, Yordan E, Beecham J. Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Invest New Drugs 1989;7:235-8.
16. Muss HB, Sutton GP, Brian B, Hatch KD. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma: A phase II study of the Gynecological Oncology Group. Am J Clin Oncol (CCT) 1985;8:312-5.